Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study 
Introduction
Ascites is pathologic accumulation of peritoneal fluid which is typically associated with a significant volume and hormonal dysregulation in the setting of cirrhosis and portal hypertension [1] . Ascites is a common complication of cirrhosis, with 60% of cirrhotics developing ascites within 10 years of diagnosis [2] . In addition, ascites and other associated complications (spontaneous bacterial peritonitis, hepatohydrothorax, hepatorenal syndrome, and malnutrition) are associated with poor prognosis [1] .
The current treatment for ascites consists of different modalities including dietary sodium restriction, pharmacologic therapies, diagnostic and therapeutic paracentesis, and transjugular intra-hepatic portosystemic shunt (TIPSS) [3, 4] . Nevertheless, these treatment modalities carry their own risks and complications, with some patients developing diuretic-induced renal dysfunction and hyponatremia as well as diuretic-resistant ascites or refractory ascites (RA). Besides liver transplant, which is the only definitive treatment for RA, large volume paracentesis (LVP) can be used for management of patients with RA [5, 6] . Although relatively safe, LVP requires patients to visit the hospital or outpatient clinics as often as weekly. In addition to LVP, TIPSS may be an option for a selected group of patients with RA [7] . Unfortunately, TIPSS placement and subsequent followup is contraindicated for some patients with cirrhosis [8, 9] .
In addition to poor clinical prognosis, many patients with ascites suffer from malnutrition [10, 11] and severe impairment of their health-related quality of life (HRQL). Several studies using both generic and disease-specific instruments have indicated that the presence of ascites is associated with severe impairment of HRQL in patients with advanced liver disease [12] [13] [14] [15] [16] . In this context, treatment of RA with alternative strategies may potentially improve patients' HRQL.
One recently developed alternative treatment for RA is the automated low-flow ascites pump system (alfapump® system, Sequana Medical AG, Zurich, Switzerland). Alfapump® (alfapump®) system is a fully implantable, programmable, and rechargeable pump system which automatically diverts ascitic fluid from the peritoneal cavity to the urinary bladder, allowing fluid removal by urination [17] . Although preliminary results have been published together with safety and efficacy outcomes, the comprehensive impact of alfapump® system on patients' HRQL has not been reported. Therefore, the purpose of this paper was to compare HRQL of patients who underwent treatment with the alfapump® system to that of patients treated with the standard of care for RA (LVP).
Methods

Patient population
In this study, we used HRQL data collected in a multicenter randomized controlled study of alfapump® versus LVP in the treatment of RA [17] . The trial was conducted in six European centers in 2012-2016 (clinicaltrials.gov #NCT01528410). Adult (18+) patients with cirrhosis confirmed by biopsy and/or clinical and/or radiologic criteria and with RA (that is, "ascites that cannot be mobilized or early recurrence of which after therapeutic paracentesis cannot be satisfactorily prevented by medical therapy" [18] ) were randomized 1:1 to either treatment with the alfapump® or evacuation LVP. Excluded were patients with recent gastrointestinal hemorrhage, severe coagulopathy or thrombocytopenia, recurring bacterial peritonitis, evidence of loculated ascites, hepatocellular carcinoma that exceeded Milan criteria, HIV infection, body mass index (BMI) > 40, and some other concomitant diseases and conditions [17] . The primary endpoint of the original study was paracentesis-free survival; the HRQL data used in this study were collected as one of the secondary endpoints.
Health-related quality of life
Health-related quality of life was assessed at screening and then at 1, 2, 3, and 6 months after the start of treatment using two widely used instruments which were self-administered by patients: Short Form-36 version 2 (SF-36v2) and the Chronic Liver Disease Questionnaire (CLDQ).
The SF-36 instrument includes 36 items grouped into eight non-overlapping domains which represent various aspects of HRQL: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), mental health (MH), all designed to range from 0 to 100. It also includes the physical (PCS) and mental (MCS) component summary scores which are linear combinations of the domains scores adjusted for the inter-domain correlations [19] . The SF-36 instrument can also be used to derive a preference-based health utility score SF-6D which is necessary for qualityadjustment of outcomes in economic analyses. For the purpose of this study, to calculate SF-6D utility scores from SF-36v2, we used a non-parametric Bayesian algorithm as described before [20] .
The CLDQ is a disease-specific instrument that was designed and validated to assess HRQL in patients with chronic liver disease (CLD), so that it focuses on the most frequently observed health-related impairments associated with living with CLD. The 29 items are grouped into six non-overlapping HRQL domains: abdominal symptoms, activity, emotional function, fatigue, systemic symptoms, and worry. The total CLDQ score is the average of the six domain scores which all range 1-7 [21] .
In both instruments, higher scores would indicate a better health status. In order to put the HRQL scores of patients with RA in context, we also collected the population norms from literature for the general population (SF-36 only [22, 23] ) as well as for patients with non-cirrhotic CLD and with CLD accompanied by compensated (Child-Pugh-Turcotte (CPT) class A) cirrhosis [24] [25] [26] [27] .
Statistical analysis
The sample size for this study was driven by the primary endpoint and was not chosen to power our HRQL analysis. Demographics and clinical parameters of the study participants were summarized as N (percentage) or mean ± standard deviation in the two treatment arms separately. The HRQL scores' changes from patients' own baseline scores were calculated for each HRQL domain and were compared to zero (which would indicate no significant change from baseline) by the sign-rank non-parametric test and between the treatment arms using the rank-sum test.
Independent association of the changes in the HRQL scores with the RA treatment choice (alfapump® vs. LVP) was assessed in a series of multiple linear regression models. Potential confounders to be adjusted for were as follows: age, gender, BMI, Model for End-stage Liver Disease (MELD) score, CPT class, etiology of CLD (alcoholic liver disease (ALD) vs. other), history of spontaneous bacterial peritonitis, renal failure, hepatorenal syndrome, hepatic encephalopathy, urinary tract infections, and variceal hemorrhage. After a series of bidirectional stepwise selection procedures, only predictors with statistically significant independent association with the outcome (p < 0.05) were kept in the models.
All analyses were run in SAS 9.3 (SAS Institute, Cary, NC). The study was separately approved by each site's Institutional Review Board.
Results
Clinical and demographic data
A total of 60 patients with refractory ascites were enrolled. Of these subjects, 58 had data to be used for safety and efficacy analysis, including 31 randomized to receive LVP and 27 assigned to the alfapump® system; the remaining two patients dropped out before the study (due to obstructive uropathy and to left inguinal hernia). Furthermore, of the intention-to-treat cohort, ten patients died before the 6 months' time point, six received a liver transplant, and four subjects discontinued the study in less than 6 months for other reasons. The HRQL data were systematically collected from all available participants for the first 3 months of treatment (N = 58 at baseline, 55 at month 1, 51 at month 2, 49 at month 3), and then from a subset of patients at month 6 (N = 28). The results of analysis of safety and efficacy endpoints have been published [17] . As reported, the use of alfapump® system led to a substantially longer time to paracentesis (hazard ratio = 0.18 (0.09-0.39), p < 0.001), less paracentesis events (1.1 vs. 8.6 per subject in 6 months after treatment initiation, with 63% of alfapump® patients needing zero paracentesis events, p < 0.001), and less ascites removed by paracentesis in the alfapump® group. No additional risks for severe adverse events, infection, or mortality were found [17, 28] .
Enrolled patients, were, on average, 61.9 ± 8.4 years of age, 79.3% male, 15% had MELD score of 15 or greater, 85.3% were CPT class B, 70.7% had alcoholic cirrhosis and 12,1% had non-alcoholic steatohepatitis (NASH), 31.0% had history of renal failure, 14.0% had hepatorenal syndrome, 31.6% had hepatic encephalopathy, 24.6% spontaneous bacterial peritonitis, 29.3% variceal hemorrhage, and 60.3% were hospitalized at least once in 3 months prior to enrollment for, on average, a total of 8.5 days. No baseline difference was found between the two treatment arms (Table 1) .
On-treatment health-related quality of life
The baseline HRQL scores of patients with RA are presented in Table 2 . As shown, all baseline scores were substantially lower in comparison to the general population norms (all p < 0.05), and nearly all scores were also significantly lower in comparison to patients with CLD without cirrhosis; the only exceptions to the latter were the mental health and emotional function scores (all p > 0.05). A number of the HRQL scores were also significantly lower in comparison to compensated cirrhosis patients: p < 0.05 for PF, RP, GH, VT, SF, and RE of SF-36, as well as for abdominal symptoms, activity, and systemic symptoms domains of CLDQ (Table 2) .
One month into treatment, improvements of some aspects of HRQL were noted in patients assigned to alfapump® ( Fig. 1; Supplementary Table 1 for the specific numbers). In particular, statistically significant improvements were noted in abdominal symptoms and systemic symptoms scores (p < 0.05), accompanied by borderline significant improvements in GH and total CLDQ scores (p < 0.10), and no decrements in other HRQL scores. On the other hand, statistically significant decrements in BP, PCS, and Fatigue scores were experienced by patients receiving LVP (p ≤ 0.05). These trends continued to be observed at the end of the second month.
At 3 months' time point, the trend towards improvement of HRQL scores in the alfapump® arm contrasted to worsening of HRQL in the LVP arm continued, and the magnitudes of improvement became more pronounced (Figs. 2, 3 , Supplementary Table 1 ). Furthermore, out of 27 patients who had an improvement in the abdominal symptoms score by month 1 and remained in the study till month 3, 81% also had an improvement in that score by month 3, suggesting that HRQL improvement was not only significant but also consistent over time (Supplementary Table 2) .
In a subgroup analysis of those who also completed 6 months HRQL questionnaires (N = 28), a similar pattern was again observed (Supplementary Table 1 ). However, due to smaller sample size reaching this time point, the differences were no longer statistically significant.
Independent predictors of HRQL scores
In multivariate analysis, the use of alfapump® was found to be independently associated with greater HRQL scores, primarily at month 3 of treatment, after adjustment for the baseline levels and other HRQL predictors. The HRQL scores found to be superior in patients using alfapump® included bodily pain (SF-36), vitality (SF-36), abdominal symptoms (CLDQ), activity (CLDQ), fatigue (CLDQ), and systemic symptoms (CLDQ) (p ≤ 0.05) ( Table 3 ). Other predictors of HRQL scores in patients with cirrhosis and RA were age, gender, alcohol-related etiology of liver disease, MELD score, CPT class, and history of complications (hepatorenal syndrome, urinary tract infection, variceal hemorrhage) (Supplementary Table 3 ).
Discussion
This is the first study assessing HRQL of cirrhotic patients with refractory ascites who have undergone treatment with LVP or alfapump® system. Our study confirms severe impairment of HRQL in patients with severe decompensated cirrhosis with refractory ascites. Additionally, our data show independent predictors of poor HRQL prior to treatment in patients with severe liver disease which includes the diagnosis of ALD and male gender. These are consistent with previously reported data [14, 27, 29, 30] .
Our results during the treatment period indicate a number of important observations. In particular, subjects with refractory ascites who are treated with LVP continue to worsen their HRQL and experience no HRQL benefit. In contrast, subjects with refractory ascites who were treated with alfapump® system did experience improvement of HRQL as early as 1 month after treatment initiation. In fact, this improvement continued with longer follow-up of those subjects, and clinically meaningful HRQL superiority was noted in multiple domains related to bodily pain, other systemic symptoms, and fatigue [24, 31, 32] . It is also important to note that the superiority of HRQL in patients treated with alfapump® remained significant even after controlling for other known predictors of HRQL scores. This supports HRQL-related benefits of alfapump® system over LVP. Interestingly, of the two HRQL instruments used, the most consistent improvements were primarily captured by the domains of CLDQ and, in particular, its abdominal symptoms domain. This suggests that in patients with advanced liver disease, a disease-specific rather than a generic HRQL instrument is more suitable for capturing changes in HRQL with treatment. This is also consistent with known responsiveness superiority of disease-specific instruments, such as CLDQ [33] .
The major limitation for this study is that our sample size was small and became smaller over time as a result of patients dying or receiving liver transplantation. In fact, we were unable to reliably report HRQL at 6 months postalfapump® insertion because less than half of initially enrolled patients were still available and able to complete the HRQL questionnaires. Despite this, our results suggest that patients with decompensated cirrhosis and RA are still able to experience improvement in their HRQL with successful treatment with alfapump®. In summary, these preliminary data suggest that receiving alfapump® for treatment of refractory ascites is associated with better HRQL scores than LVP. In this context, we propose that obtaining patients' perspective via assessment of HRQL scores should accompany clinical outcomes and resource utilization metrics in order to assess the full impact of the new treatments. These data, coupled with efficacy, safety, and cost can inform caregivers and policy makers regarding their decisions on how best to best manage important complications of cirrhosis and to provide access to new treatment modalities.
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